- All sections
- C - Chemistry; metallurgy
- C07D - Heterocyclic compounds
- C07D 249/04 - 1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
Patent holdings for IPC class C07D 249/04
Total number of patents in this class: 849
10-year publication summary
54
|
62
|
62
|
56
|
49
|
66
|
63
|
48
|
60
|
14
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Theravance Biopharma R&D IP, LLC | 550 |
50 |
The Johns Hopkins University | 5377 |
18 |
Modernatx, Inc. | 1181 |
13 |
Yale University | 2204 |
13 |
The Regents of the University of California | 18943 |
11 |
The Scripps Research Institute | 1364 |
10 |
Merck Sharp & Dohme LLC | 3689 |
9 |
Boehringer Ingelheim International GmbH | 4629 |
8 |
Bristol-myers Squibb Company | 5080 |
7 |
Glaxosmithkline Intellectual Property Development Limited | 723 |
7 |
Siemens Medical Solutions USA, Inc. | 1584 |
7 |
Board of Regents, The University of Texas System | 5370 |
7 |
ABA Chemicals Corporation | 24 |
7 |
Emory University | 1498 |
7 |
The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth, Near Dublin | 157 |
7 |
The University of Queensland | 666 |
7 |
Inflazome Limited | 92 |
7 |
Sigilon Therapeutics, Inc. | 82 |
7 |
Syngenta Participations AG | 4970 |
6 |
Abbvie Inc. | 1808 |
6 |
Other owners | 635 |